Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

437 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries.
Balkau B, Deanfield JE, Després JP, Bassand JP, Fox KA, Smith SC Jr, Barter P, Tan CE, Van Gaal L, Wittchen HU, Massien C, Haffner SM. Balkau B, et al. Among authors: barter p. Circulation. 2007 Oct 23;116(17):1942-51. doi: 10.1161/CIRCULATIONAHA.106.676379. Circulation. 2007. PMID: 17965405 Free PMC article.
Usefulness of measuring both body mass index and waist circumference for the estimation of visceral adiposity and related cardiometabolic risk profile (from the INSPIRE ME IAA study).
Nazare JA, Smith J, Borel AL, Aschner P, Barter P, Van Gaal L, Tan CE, Wittchen HU, Matsuzawa Y, Kadowaki T, Ross R, Brulle-Wohlhueter C, Alméras N, Haffner SM, Balkau B, Després JP; INSPIRE ME IAA Investigators. Nazare JA, et al. Among authors: barter p. Am J Cardiol. 2015 Feb 1;115(3):307-15. doi: 10.1016/j.amjcard.2014.10.039. Epub 2014 Nov 13. Am J Cardiol. 2015. PMID: 25499404
Visceral, subcutaneous abdominal adiposity and liver fat content distribution in normal glucose tolerance, impaired fasting glucose and/or impaired glucose tolerance.
Borel AL, Nazare JA, Smith J, Aschner P, Barter P, Van Gaal L, Eng Tan C, Wittchen HU, Matsuzawa Y, Kadowaki T, Ross R, Brulle-Wohlhueter C, Alméras N, Haffner SM, Balkau B, Després JP. Borel AL, et al. Among authors: barter p. Int J Obes (Lond). 2015 Mar;39(3):495-501. doi: 10.1038/ijo.2014.163. Epub 2014 Sep 2. Int J Obes (Lond). 2015. PMID: 25179244
Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity.
Ross R, Neeland IJ, Yamashita S, Shai I, Seidell J, Magni P, Santos RD, Arsenault B, Cuevas A, Hu FB, Griffin BA, Zambon A, Barter P, Fruchart JC, Eckel RH, Matsuzawa Y, Després JP. Ross R, et al. Among authors: barter p. Nat Rev Endocrinol. 2020 Mar;16(3):177-189. doi: 10.1038/s41574-019-0310-7. Epub 2020 Feb 4. Nat Rev Endocrinol. 2020. PMID: 32020062 Free PMC article. Review.
Assessment of cardiometabolic risk and prevalence of meeting treatment guidelines among patients with type 2 diabetes stratified according to their use of insulin and/or other diabetic medications: results from INSPIRE ME IAA.
Smith J, Nazare JA, Borel AL, Aschner P, Barter PJ, Van Gaal L, Matsuzawa Y, Kadowaki T, Ross R, Brulle-Wohlhueter C, Alméras N, Haffner SM, Balkau B, Després JP. Smith J, et al. Among authors: barter pj. Diabetes Obes Metab. 2013 Jul;15(7):629-41. doi: 10.1111/dom.12075. Epub 2013 Feb 24. Diabetes Obes Metab. 2013. PMID: 23356633
Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement.
Neeland IJ, Ross R, Després JP, Matsuzawa Y, Yamashita S, Shai I, Seidell J, Magni P, Santos RD, Arsenault B, Cuevas A, Hu FB, Griffin B, Zambon A, Barter P, Fruchart JC, Eckel RH; International Atherosclerosis Society; International Chair on Cardiometabolic Risk Working Group on Visceral Obesity. Neeland IJ, et al. Among authors: barter p. Lancet Diabetes Endocrinol. 2019 Sep;7(9):715-725. doi: 10.1016/S2213-8587(19)30084-1. Epub 2019 Jul 10. Lancet Diabetes Endocrinol. 2019. PMID: 31301983 Free article. Review.
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.
Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, Kastelein JJ, LaRosa JC, Schachner H, Shepherd J, Waters DD; Treating to New Targets Investigators. Deedwania P, et al. Among authors: barter p. Lancet. 2006 Sep 9;368(9539):919-28. doi: 10.1016/S0140-6736(06)69292-1. Lancet. 2006. PMID: 16962881 Clinical Trial.
Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease.
Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Granger C, Menon V, Montalescot G, Rader D, Tall AR, McErlean E, Wolski K, Ruotolo G, Vangerow B, Weerakkody G, Goodman SG, Conde D, McGuire DK, Nicolau JC, Leiva-Pons JL, Pesant Y, Li W, Kandath D, Kouz S, Tahirkheli N, Mason D, Nissen SE; ACCELERATE Investigators. Lincoff AM, et al. N Engl J Med. 2017 May 18;376(20):1933-1942. doi: 10.1056/NEJMoa1609581. N Engl J Med. 2017. PMID: 28514624 Free article. Clinical Trial.
Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial.
Nicholls SJ, Lincoff AM, Barter PJ, Brewer HB, Fox KA, Gibson CM, Grainger C, Menon V, Montalescot G, Rader D, Tall AR, McErlean E, Riesmeyer J, Vangerow B, Ruotolo G, Weerakkody GJ, Nissen SE. Nicholls SJ, et al. Am Heart J. 2015 Dec;170(6):1061-9. doi: 10.1016/j.ahj.2015.09.007. Epub 2015 Sep 16. Am Heart J. 2015. PMID: 26678626 Clinical Trial.
437 results